X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ASTRAZENECA PHARMA AJANTA PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 20.9 93.7 22.3% View Chart
P/BV x 9.1 13.3 67.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AJANTA PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
AJANTA PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,285 133.9%   
Low Rs1,103634 174.0%   
Sales per share (Unadj.) Rs194.6189.6 102.6%  
Earnings per share (Unadj.) Rs45.2-0.2 -22,209.8%  
Cash flow per share (Unadj.) Rs50.33.8 1,308.3%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.068.6 192.4%  
Shares outstanding (eoy) m88.7725.00 355.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.35.1 143.3%   
Avg P/E ratio x31.2-4,712.7 -0.7%  
P/CF ratio (eoy) x28.1249.6 11.2%  
Price / Book Value ratio x10.714.0 76.5%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29923,988 522.4%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,5701,605 160.2%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m17,2754,740 364.5%  
Other income Rs m16692 180.6%   
Total revenues Rs m17,4424,832 361.0%   
Gross profit Rs m5,807-130 -4,474.0%  
Depreciation Rs m451101 445.3%   
Interest Rs m490-   
Profit before tax Rs m5,474-139 -3,941.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,4605 28,681.7%   
Profit after tax Rs m4,014-5 -78,862.5%  
Gross profit margin %33.6-2.7 -1,227.5%  
Effective tax rate %26.7-3.7 -727.8%   
Net profit margin %23.2-0.1 -21,637.0%  
BALANCE SHEET DATA
Current assets Rs m7,6392,726 280.2%   
Current liabilities Rs m2,7152,435 111.5%   
Net working cap to sales %28.56.1 463.6%  
Current ratio x2.81.1 251.3%  
Inventory Days Days4374 58.6%  
Debtors Days Days7941 193.0%  
Net fixed assets Rs m6,9141,035 667.8%   
Share capital Rs m17750 353.8%   
"Free" reserves Rs m11,442942 1,214.1%   
Net worth Rs m11,7211,716 683.0%   
Long term debt Rs m1490-   
Total assets Rs m14,8144,156 356.5%  
Interest coverage x112.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.1 102.3%   
Return on assets %27.4-0.1 -22,393.6%  
Return on equity %34.2-0.3 -11,546.2%  
Return on capital %46.50-  
Exports to sales %55.15.7 967.4%   
Imports to sales %6.06.5 92.9%   
Exports (fob) Rs m9,527270 3,525.9%   
Imports (cif) Rs m1,038306 338.8%   
Fx inflow Rs m10,422375 2,782.1%   
Fx outflow Rs m1,678470 356.9%   
Net fx Rs m8,744-96 -9,150.8%   
CASH FLOW
From Operations Rs m3,264-8 -40,293.8%  
From Investments Rs m-2,093-146 1,436.4%  
From Financial Activity Rs m-1,186862 -137.5%  
Net Cashflow Rs m-15709 -2.1%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 15.7 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 12,856 163.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUVEN LIFE  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS